Perspectives on the use of adaptive designs in clinical trials. Part II. Panel discussion

Journal of Biopharmaceutical Statistics

Volumn 20, Issue 6, 2010, Pages 1098-1112

  Benda, Norbert ^a   Brannath, Werner ^b   Bretz, Frank ^c   Burger, Hans Ulrich ^d   Friede, Tim ^e   Maurer, Willi ^c   Wang, Sue Jane ^f  

^a FEDERAL INSTITUTE FOR DRUGS AND MEDICAL DEVICES   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c NOVARTIS PHARMA AG   (Switzerland)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

^e UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^f CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Clinical trial design; Confirmatory study; Drug development; Exploratory study

Indexed keywords

ADAPTIVE DESIGN; CLINICAL RESEARCH; CLINICAL TRIAL; CONFERENCE PAPER; CONFIRMATORY DESIGN; CONSENSUS; DRUG DEVELOPMENT; DRUG INDUSTRY; HUMAN; METHODOLOGY; PRIORITY JOURNAL; SYSTEMATIC ERROR;

CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; DRUG APPROVAL; GUIDELINES AS TOPIC; HUMANS; MODELS, STATISTICAL; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; TREATMENT OUTCOME; UNITED STATES;

EID: 78249268825     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543406.2010.514447     Document Type: Conference Paper

References (33)

1. Bauer, P. (2008). Adaptive designs: Looking for a needle in the haystack-A new challenge in medical research. Statistics in Medicine 27:1565-1580.
2. Bauer, P., Koenig, F., Brannath, W., Posch, M. (2010). Selection and bias - two hostile brothers. Statistics in Medicine 29 (1):1-13.
3. Benda, N., Branson, M., Maurer, W., Friede, T. (2010). Aspects of modernizing drug development using scenario planning and evaluation. Drug Information Journal 44:299-315.
4. Bowden, J., Glimm, E. (2008). Unbiased estimation of selected treatment means in two-stage trials. Biometrical Journal 50:515-527.
5. Brannath, W., König, F. (2008). Estimation after treatment selection. Talk at Joint the LifeStat Conference (Meeting of German and Austrian Region of the Biometrical Society), Munich.
6. Brannath, W., König, F., Bauer, P. (2006). Estimation in flexible two stage designs. Statistics in Medicine 25:3366-3381.
7. Brannath, W., König, F., Bauer, P. (2007). Multiplicity and flexibility in clinical trials. Pharmaceutical Statistics 6:205-216.
8. Bretz, F., Wang, S. J. (2010). From adaptive design to modern protocol design for drug development: Part II. Success probabilities and effect estimates for Phase III development programs. Drug Information Journal 44 (3):333-342.
9. Bretz, F., Schmidli, H., Koenig, F., Racine, A., Maurer, W. (2006) Confirmatory seamless Phase II/III clinical trials with hypotheses selection at interim: General concepts (with discussion). Biometrical Journal 48:623-634. (Pubitemid 44367905)
10. Bretz, F., Koenig, F., Brannath, W., Glimm, E., Posch, M. (2009a). Tutorial in biostatistics: Adaptive designs for confirmatory clinical trials. Statistics in Medicine 28:1181-1217.
11. Bretz, F., Branson, M., Burman, C. F., Chuang-Stein, C., Coffey, C. S. (2009b). Adaptivity in drug discovery and development. Drug Development Research 70:169-190.
12. Chataway, J., Nicholas, R., Todd, S., Parsons, N., Todd, S., Miller, D., Valdés-Márquez, E., Stallard, N., Friede, T. (2010). A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis. Available at: msj.sajepub.com/content/ early/2010/08/25/1352458510382129.abstract
13. European Medicines Agency. (2007a). Innovative Drug Development Approaches. Final Report from the EMEA/CHMP-Think-Tank Group on Innovative Drug Development Approaches. Available at: www.emea.europa.eu/pdfs/human/itf/ 12731807en.pdf
14. European Medicines Agency. (2007b). Reflection Paper on Methodological Issues in Confirmatory Clinical Trials Planned with an Adaptive Design. Available at www.emea.europa.eu/pdfs/human/ewp/245902enadopted.pdf
15. Food and Drug Administration. (2004). Innovation/Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products. FDA Report, March. Available at www.fda.gov/oc/initiatives/criticalpath/whitepaper.html
16. Food and Drug Administration. (2006). Innovation/Stagnation: Critical Path Opportunities Report. FDA Report, March. Available at www.fda.gov/oc/ initiatives/criticalpath/reports/opp-report.pdf
17. Food and Drug Administration. (2010). Draft Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics. Available at www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ UCM201790.pdf. Released on February 25, 2010, for public comments.
18. Friede, T., Nicholas, R., Stallard, N., Todd, S., Parsons, N., Valdés-Márquez, E., Chataway, J. (2010a). Refinement of the clinical scenario evaluation framework for assessment of competing development strategies with an application to multiple sclerosis. Drug Information Journal (submitted).
19. Friede, T., Schmidli, H. (2010). Blinded sample size reestimation with count data: Methods and applications in multiple sclerosis. Statistics in Medicine 29:1145-1156.
20. Friede, T., Parsons, N., Stallard, N., Todd, S., Valdés- Márquez, E., Chataway, J., Nicholas, R. (2010b). Designing a seamless Phase II/III clinical trial using early outcomes for treatment selection: An application in multiple sclerosis. (In press.)
21. Gallo, P., Chuang-Stein, C., Dragalin, V., Gaydos, B., Krams, M., Pinheiro, J. (2006). Adaptive designs in clinical drug development - An executive summary of the PhRMA Working Group. Journal of Biopharmaceutical Statistics 16:275-283.
22. Glimm, E., Maurer, W., Bretz, F. (2010). Hierarchical testing of multiple endpoints in group sequential trials. Statistics in Medicine 29:219-228.
23. Guilbaud, D. (2009). Simultaneous confidence intervals regions corresponding to Holm's step-down procedure and other closted-testing procedures. Biometrical Journal 51:721-735.
24. International Conference on Harmonization. (1998). International Conference on Harmonization (ICH) Guidance, E8 General Considerations for Clinical Trials. Available at www.ich.org/LOB/media/MEDIA484.pdf
25. Posch, M., Koenig, F., Branson, M., Brannath, W., Dunger-Baldauf, C., Bauer, P. (2005). Testing and estimation in flexible group sequential designs with adaptive treatment selection. Statistics in Medicine 24:3697-3714.
26. Posch, M., Maurer, W., Bretz, F. (2010). Type I error rate control in adaptive designs for confirmatory clinical trials with treatment selection at interim. Pharmaceutical Statistics (in press). doi: 10.1002/pst.413.
27. Schaefer, H., Timmesfeld, N., Mueller, H.-H. (2006). An overview of statistical approaches for adaptive designs and design modifications. Biometrical Journal 48:507-520.
28. Stallard, N. (2010). A confirmatory seamless Phase II/III clinical trial design incorporating short-term endpoint information. Statistics in Medicine 29:959-971.
29. Stallard, N., Friede, T. (2010). Efficiency of adaptive designs. In: Chow, Pong, eds. Handbook of Adaptive Designs in Pharmaceutical and Clinical Development. New York: Taylor & Francis (in press).
30. Stallard, N., Todd, S. (2005). Point estimates and confidence regions for sequential trials involving selection. Journal of Statistical Planning and Inference 135:402-419.
31. Strassburger, K., Bretz, F. (2008). Compatible simultaneous lower confidence bounds for the Holm procedure and other Bonferroni based closed tests. Statistics in Medicine 27:4914-4927.
32. Wang, S. J. (2010). Perspectives on the use of adaptive designs in clinical trials. Part I. Statistical considerations and issues. Journal of Biopharmaceutical Statistics (this issue).
33. Wang, S. J., Hung, H. M. J., O'Neill, R. (2010). Adaptive design clinical trials and trial logistics models in CNS drug development. European Neuropsychopharmacology 2010. doi:10.1016/euroneuro.2010.09.003.